Cryoprecipitate

• Cryoprecipitate is prepared by freezing and then thawing plasma at which time a cryoprecipitate occurs which contains a high concentration of factor VIII fibrinogen, fibronectin and factor XIII.
• Cryoprecipitate (Lyophilised) is prepared from a single donation of apheresis plasma obtained from NZ volunteer donors.  It is processed within 6 hours of collection.  It is suspended in buffer under sterile conditions and then lyophilised and heat treated.
• Cryoprecipitate should be ABO compatible wherever possible.

Indications

• Cryoprecipitate is now mainly used as a source of fibrinogen.
• Cryoprecipitate is sometimes used for the treatment of haemophilia A, where there is a demonstrated deficiency of activity of the plasma clotting factor (AHF Factor VIII). However the product of choice is Recombinant Factor 8 (synthetic derived product).
• Can be used for the treatment of patients with fibrin stabilising factor (Factor XIII deficiency).
  The reconstituted product will contain approximately 200 units of Factor XIII).
• Von-Willebrands Syndrome.

Dosage

• 10 – 20ml/kg.
• Cryoprecipitate does not contain an antimicrobial preservative and is therefore readily susceptible to contamination.

Storage

• Frozen cryoprecipitate is stable for one year at -30
• Shelf life is 6 hours when stored in Blood Fridge.  When unit arrives in Newborn Services it must be used within 2 hours.
• Must be transfused within 6 hours of thawing.  It will have a yellow expiratory sticker on stating date and time of expiry.  Do not refrigerate after thawing as otherwise insoluble cryoprecipitate may reform.

Checking, Administration, Monitoring, and Documentation

• As for blood and blood products.
• Checking
• Administration
• Monitoring
• Documentation

Adverse Reactions

• See Transfusion Reactions.